Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | terminated | Phase 2 | 442 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2018 | clinicaltrials |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | terminated | Phase 1 | 50 | PlexxikonINDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT02785900 |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia(CASCADE) |
| terminated |
| Phase 3 |
| 240 |
| Seagen Inc.INDUSTRY |
| 16 |
| Dec 12, 2018 |
| clinicaltrials |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00212407 | New York Blood Center National Cord Blood Program | terminated | Early Phase 1 | 4,476 | New York Blood CenterOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT02709083 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 17 | Stanford UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY(SAMBA) | terminated | Phase 2 | 25 | GWT-TUD GmbHOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 28 | CelgeneINDUSTRY | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01866553 | Nilotinib Plus Pegylated Interferon-α2b in CML | terminated | Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 5 | Oct 12, 2018 | clinicaltrials |
| NCT00038649 | Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | terminated | Phase 2 | 117 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 13 | David IberriOTHER | 1 | Sep 27, 2018 | clinicaltrials |
| NCT02415608 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | terminated | Phase 2 | 4 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00398047 | Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 2 | 3 | Wake Forest University Health SciencesOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01397734 | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) | terminated | Phase 1 | 7 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00907517 | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) | terminated | Phase 1 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01451437 | Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) | terminated | Phase 1 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT00939159 | Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00356928 | Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | terminated | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | terminated | Phase 2 / Phase 3 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | terminated | Phase 2 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01490775 | Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy | terminated | N/A | 27 | Rex Cancer Center, Raleigh, NCOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT01490983 | Telemonitoring Study - for Chronic Myeloid Leukemia (CML) | terminated | N/A | 14 | Rex Cancer Center, Raleigh, NCOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00104806 | Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 2 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01598025 | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | terminated | N/A | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome(AML/MDS) | terminated | Phase 1 / Phase 2 | 13 | Biosuccess Biotech Co., Ltd.INDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01761695 | Chronic Myelod Leukemia Registry at Asan Medical Center | terminated | — | 100 | Asan Medical CenterOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | terminated | Phase 4 | 55 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02532010 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML(Pacritinib) | terminated | Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | — | 56 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02635074 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 2 | Steven E. CoutreOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02848248 | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 17 | Seagen Inc.INDUSTRY | 1 | May 14, 2018 | clinicaltrials |
| NCT00118196 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | terminated | Phase 2 | 1 | Medical University of South CarolinaOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | terminated | Phase 2 | 9 | Sherif S. FaragOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2018 | clinicaltrials |
| NCT02519712 | Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors | terminated | N/A | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2018 | clinicaltrials |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | terminated | Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00113646 | Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 14 | Massachusetts General HospitalOTHER | 1 | Mar 16, 2018 | clinicaltrials |
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02198482 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 6 | University of UlmOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT02631252 | Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | terminated | Phase 1 | 1 | Alison Sehgal, MD, MSOTHER | 1 | Feb 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 31, 2018source: clinicaltrials